Covaxin
Indian drug regulator DGCI clears Covaxin phase 2, 3 clinical trials for children
New Delhi/IBNS: India's drug regulator body has cleared the second and third phase of clinical trials of indigenous anti-Covid-19 vaccine, Covaxin, for children, media reports said.
The trails have been permitted by the Drugs Controller General of India (DGCI) for children aged two to 18.
Bharat Biotech, the manufacturer of Covaxin, has stated it will carry out the trials on "525 healthy volunteers".
The trial will involve the injection of two doses on day 0 and 28.
The Subject Expert Committee (SEC) has put up a condition to Bharat Biotech that the firm should submit its interim safety data of phase two trial before proceeding to the next phase.
For all adults, i.e. individuals aged 18 or more, the government has permitted two vaccines, Covaxin and Oxford University's Covishield, which is developed by Serum Institute of India in the country.
Support Our Journalism
We cannot do without you.. your contribution supports unbiased journalism
IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.
Support objective journalism for a small contribution.
